CorMedix (CRMD) Leerink Global Healthcare Conference 2026 summary

Strategic focus and business evolution

• Transitioned from a single-product company to a diversified specialty pharma with the Melinta acquisition in 2025, expanding into institutional care settings and broadening the product portfolio, especially in anti-infectives.

• Focus shifted from a specific therapeutic area to leveraging commercial infrastructure across hospitals and infusion clinics, with two assets in development: REZZAYO (Phase 3, prophylaxis of invasive fungal infections) and DefenCath (Phase 3, CLABSI prevention in TPN patients).

• REZZAYO Phase 3 data readout expected mid-to-late Q2, potentially expanding into hematology-oncology clinics.

• DefenCath Phase 3 for TPN patients targeted for completion in early 2027, with ongoing focus on institutional and home care settings.

• Multiple catalysts anticipated over the next 12–18 months.

DefenCath performance and growth drivers

• Demonstrated 70% reduction in CRBSIs and hospitalizations in both clinical and real-world settings, leading to significant healthcare cost savings.

• Maximized value during the two-year TDAPA reimbursement window, now focusing on stabilizing patient volumes as the window ends in June, with strategies to grow utilization among Medicare Advantage patients.

• Leveraging real-world evidence, especially from U.S. Renal Care, to negotiate with Medicare Advantage plans for separate reimbursement and to support value for dialysis providers.

• Inpatient segment represents about 10% of dialysis volume, with renewed focus following field team integration post-Melinta acquisition.

• Guidance aims to maintain patient volumes through 2027, with potential upside from Medicare Advantage, new customers, and inpatient uptake.

REZZAYO development and market opportunity

• REZZAYO is a long-acting echinocandin, once-weekly IV, currently indicated for Candida infections; Phase 3 study targets prophylaxis in immunocompromised patients.

• Study design: 650 patients, head-to-head vs. standard of care (azole + Bactrim), primary endpoint is fungal-free survival at day 90, secondary is discontinuation rate.

• Differentiators include lower hepatotoxicity and fewer drug-drug interactions compared to azoles, with potential to simplify regimens and reduce discontinuations.

• Prophylaxis market opportunity estimated at $500 million for BMT patients, with additional potential in solid organ transplant and spillover markets.

• Commercial strategy post-positive data includes modest team expansion, targeted outreach, and aiming for a Q1 2027 launch.